FRO7 Antibody

FZD7 Antibodies: Overview and Mechanisms

FZD7 (Frizzled 7) is a Wnt receptor frequently overexpressed in cancers, including breast, ovarian, and colorectal cancers . Anti-FZD7 antibodies aim to block Wnt signaling, inhibit tumor growth, and induce apoptosis.

Key Antibody Formats and Functions

2.1. scFv Fragment Development

In a study by , a recombinant scFv anti-FZD7 antibody was engineered in E. coli. Key results:

• Expression: Single 31 kDa band confirmed via Western blot .

• Binding Specificity:

  • Bound 21.5% of MDA-MB-231 breast cancer cells (FZD7-high).

  • Minimal binding to SKBR-3 cells (negative control) .

• Functional Impact:

  • Apoptosis: 73.7% induction in MDA-MB-231 cells (vs. 29.5% in SKBR-3) .

  • Migration/Invasion: 76% and 58% inhibition, respectively .

2.2. Synthetic Broad-Spectrum Antibodies

Phage display engineering yielded pan-FZD antibodies targeting FZD1, 2, 4, 5, 7, and 8 . Notable outcomes:

• Efficacy: Superior to first-generation antibodies (e.g., OMP-18R5) in inhibiting Wnt3A signaling .

• Angiogenesis Suppression: Reduced endothelial cell growth, enhancing anti-tumor effects .

2.3. Antibody-Drug Conjugates (ADCs)

Septuximab vedotin (F7-ADC) combines a chimeric anti-FZD7 antibody with monomethyl auristatin E (MMAE) :

• Specificity: Binds FZD7 with high affinity, sparing normal tissues .

• In Vivo Efficacy:

  • Ovarian Tumor Xenografts: Significant regression in murine models .

  • Safety: No acute toxicity observed in transgenic mice expressing humanized Fzd7 .

Challenges and Future Directions

• Off-Target Effects: FZD7 shares structural homology with other FZDs; pan-FZD antibodies mitigate this but require precise specificity engineering .

• Clinical Translation: F7-ADC shows promise for ovarian cancer but requires further toxicology studies .